HAYWARD, Calif.-- Acologix, Inc., a privately held biopharmaceutical company, has announced that Phase II clinical trial results for AC-100 (Dentonin) will be presented during an oral presentation in the "Late Breaking News Session" at the Annual Meeting of the American Association for Dental Research in Orlando, Fla.
The abstract (#2225), entitled "AC-100, Novel Biological Approach to Promoting Dentin Formation in Humans," will be presented by Mirella Lazarov, DDS, PhD, director of Pre-Clinical Development at Acologix, on March 10 at 9:07 a.m. EST in the Walt Disney World Dolphin Hotel, Room Oceanic 1.
"We look forward to presenting these Phase II clinical trial results for AC-100 at the AADR annual meeting, one of the premier dental conferences in the world," said Yoshi Kumagai, president and CEO of Acologix.
"Based on evidence observed to date, we believe that AC-100 represents a novel and promising approach for promoting dentin formation in patients undergoing dental restoration procedures, and could potentially change the way these patients are treated in the future. This is a large and underserved market with more than 200 million dental procedures performed annually in the U.S."
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells. It is being developed by Acologix for dental, periodontal and orthopedic applications.
AC-100 is currently being studied in two Phase II clinical trials for hard tissue regeneration (i.e., dentin regeneration for dental procedures and oral bone regeneration for periodontal disease).
